January 25, 2016

Company Name	3-D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
TEL	+81 3 (3511)3440

Absorbable Hemostat PuraStat®
Product Registration Obtained in Thailand

The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company hereby announces that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Thailand has been granted by the regulatory body, Food and Drug Administration Thailand (FDA Thailand).

The group has obtained CE marking for the absorbable hemostat PuraStat® on January 14, 2014. This CE marking can be leveraged by using it as a reference regulatory agency approval in various countries in Asia-Pacific and Latin America. The product can be commercially marketed once approval is obtained in each country.

With this medical device product registration approval, marketing and sales activities in Thailand can start.

3DMA had already entered into a partnership agreement with Daewoong Pharmaceutical Co., Ltd. ("Daewoong", head office located in Seoul, Korea, President & CEO Jong-Wook Lee) for sales and marketing of PuraStat® in Thailand during the 1st quarter of fiscal year 2016. With this FDA Thailand approval, 3DMA will start initial exportation of PuraStat® to Thailand this quarter and begin sales and marketing activities through Daewoong early next quarter.

The impact on the company's earning is minimal at this point. This announcement does not influence the earning forecast of the company at this moment. However, should there be any changes, announcement will be made promptly.